Current Pain and Headache Reports

, Volume 15, Issue 1, pp 79–83 | Cite as

Update on Medication-overuse Headache

  • Milena De Felice
  • Michael H. Ossipov
  • Frank Porreca


Medication-overuse headache (MOH) is a syndrome that can develop in migraineurs after overuse of antimigraine drugs, including opiates and triptans especially. MOH manifests as increased frequency and intensity of migraine attacks and enhanced sensitivity to stimuli that elicit migraine episodes. Although the mechanisms underlying MOH remain unknown, it is hypothesized that repeated use of antimigraine drugs could elicit increased headache attacks as a consequence of neuronal plasticity that may increase responsiveness to migraine triggers. Preclinical studies show that exposure to either opiates or triptans can induce pronociceptive neuroadaptive changes in the orofacial division of the trigeminal ganglia that persist even after discontinuation of the drug treatment. Additionally, medications can elicit increased descending facilitatory influences that may amplify evoked inputs from trigeminal afferents leading to behavioral hypersensitivity reminiscent of cutaneous allodynia observed clinically. Importantly, enhanced descending facilitation may manifest as an inhibition of diffuse noxious inhibitory control. Persistent, pronociceptive adaptations in nociceptors as well as within descending modulatory pathways thus may jointly contribute to the development of MOH.


Migraine Medication-overuse headache Opiates Triptans Neuroadaptive changes 


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Silberstein SD, Olesen J, Bousser MG, et al.: The International Classification of Headache Disorders, 2nd Edition (ICHD-II): revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005, 25:460–465. (Published erratum appears in Cephalalgia 2006, 26:360.)PubMedCrossRefGoogle Scholar
  2. 2.
    Fritsche G, Frettloh J, Huppe M, et al.: Prevention of medication overuse in patients with migraine. Pain 2010 Aug 26 (Epub ahead of print).Google Scholar
  3. 3.
    Calabresi P, Cupini LM: Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci 2005, 26:62–68.PubMedCrossRefGoogle Scholar
  4. 4.
    Fuh JL, Wang SJ, Lu SR, Juang KD: Does medication overuse headache represent a behavior of dependence? Pain 2005, 119:49–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Radat F, Creac’h C, Guegan-Massardier E, et al.: Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache 2008, 48:1026–1036.PubMedCrossRefGoogle Scholar
  6. 6.
    Lundqvist C, Aaseth K, Grande RB, et al.: The severity of dependence score correlates with medication overuse in persons with secondary chronic headaches. The Akershus study of chronic headache. Pain 2010, 148:487–491.PubMedCrossRefGoogle Scholar
  7. 7.
    Dodick D, Freitag F: Evidence-based understanding of medication-overuse headache: clinical implications. Headache 2006, 46(Suppl 4):S202–S211.PubMedCrossRefGoogle Scholar
  8. 8.
    Dodick DW: Clinical practice. Chronic daily headache. N Engl J Med 2006, 354:158–165. (Published erratum appears in N Engl J Med 2006, 354:884.)PubMedCrossRefGoogle Scholar
  9. 9.
    Bahra A, Walsh M, Menon S, Goadsby PJ: Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003, 43:179–190.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Bigal ME, Lipton RB: Excessive acute migraine medication use and migraine progression. Neurology 2008, 71:1821–1828. This article includes clinical evidence for medication-overuse headache.PubMedCrossRefGoogle Scholar
  11. 11.
    Bigal ME, Serrano D, Buse D, et al.: Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008, 48:1157–1168.PubMedCrossRefGoogle Scholar
  12. 12.
    Diamond S, Bigal ME, Silberstein S, et al.: Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007, 47:355–363. (Published eratum appears in Headache 2007, 47:1365.)PubMedGoogle Scholar
  13. 13.
    Limmroth V, Katsarava Z, Fritsche G, et al.: Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002, 59:1011–1014.PubMedGoogle Scholar
  14. 14.
    Katsarava Z, Diener HC, Limmroth V: Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf 2001, 24:921–927.PubMedCrossRefGoogle Scholar
  15. 15.
    Katsarava Z, Fritsche G, Muessig M, et al.: Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001, 57:1694–1698.PubMedGoogle Scholar
  16. 16.
    Bigal ME, Ashina S, Burstein R, et al.: Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008, 70:1525–1533.PubMedCrossRefGoogle Scholar
  17. 17.
    Lipton RB, Bigal ME, Ashina S, et al.: Cutaneous allodynia in the migraine population. Ann Neurol 2008, 63:148–158.PubMedCrossRefGoogle Scholar
  18. 18.
    Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614–624.PubMedCrossRefGoogle Scholar
  19. 19.
    Dodick D, Silberstein S: Central sensitization theory of migraine: clinical implications. Headache 2006, 46(Suppl 4):S182–S191.PubMedCrossRefGoogle Scholar
  20. 20.
    •• Bigal ME, Lipton RB: Excessive opioid use and the development of chronic migraine. Pain 2009, 142:179–182. This article includes clinical evidence for medication-overuse headache induced by opioids.PubMedCrossRefGoogle Scholar
  21. 21.
    •• Moulton EA, Burstein R, Tully S, et al.: Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One 2008, 3:e3799. This article shows functional magnetic resonance imaging evidence of activation of nociceptive pathways associated with headache disorders.PubMedCrossRefGoogle Scholar
  22. 22.
    Burstein R, Cutrer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123(Pt 8):1703–1709.PubMedCrossRefGoogle Scholar
  23. 23.
    Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89:107–110.PubMedCrossRefGoogle Scholar
  24. 24.
    •• Edelmayer RM, Vanderah TW, Majuta L, et al.: Medullary pain facilitating neurons mediate allodynia in headache-related pain. Ann Neurol 2009, 65:184–193. This article includes preclinical evidence of allodynia associated with dural stimulation as well as the requirement for activation of descending facilitation from the RVM for the expression of allodynia.PubMedCrossRefGoogle Scholar
  25. 25.
    Oshinsky ML, Gomonchareonsiri S: Episodic dural stimulation in awake rats: a model for recurrent headache. Headache 2007, 47:1026–1036.PubMedCrossRefGoogle Scholar
  26. 26.
    Strassman AM, Raymond SA, Burstein R: Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560–564.PubMedCrossRefGoogle Scholar
  27. 27.
    Burstein R, Yamamura H, Malick A, Strassman AM: Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998, 79:964–982.PubMedGoogle Scholar
  28. 28.
    Yamamura H, Malick A, Chamberlin NL, Burstein R: Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. J Neurophysiol 1999, 81:479–493.PubMedGoogle Scholar
  29. 29.
    Porreca F, Ossipov MH, Gebhart GF: Chronic pain and medullary descending facilitation. Trends Neurosci 2002, 25:319–325.PubMedCrossRefGoogle Scholar
  30. 30.
    Gardell LR, Wang R, Burgess SE, et al.: Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002, 22:6747–6755.PubMedGoogle Scholar
  31. 31.
    Meng CQ, Rakhit S, Lee DK, et al.: 5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine. Bioorg Med Chem Lett 2000, 10:903–905.PubMedCrossRefGoogle Scholar
  32. 32.
    •• De Felice M, Porreca F: Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia 2009, 29:1277–1284. This article shows preclinical evidence of morphine-induced neuroadaptive changes in dural afferent of the trigeminal ganglia.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Okada-Ogawa A, Porreca F, Meng ID: Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons. J Neurosci 2009, 29:15828–15835. This article demonstrates loss of DNIC in rats after exposure to chronic morphine.PubMedCrossRefGoogle Scholar
  34. 34.
    Cathcart S, Winefield AH, Lushington K, Rolan P: Noxious inhibition of temporal summation is impaired in chronic tension-type headache. Headache 2010, 50:403–412.PubMedCrossRefGoogle Scholar
  35. 35.
    de Tommaso M, Sardaro M, Pecoraro C, et al.: Effects of the remote C fibres stimulation induced by capsaicin on the blink reflex in chronic migraine. Cephalalgia 2007, 27:881–890.PubMedCrossRefGoogle Scholar
  36. 36.
    •• Perrotta A, Serrao M, Sandrini G, et al.: Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia 2010, 272–284. This article includes evidence of loss of DNIC in patients with MOH.Google Scholar
  37. 37.
    •• De Felice M, Ossipov MH, Wang R, et al.: Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 2010, 67:325–337. This article shows preclinical evidence that repeated exposure to triptans lead to neuroadaptive changes that may be responsible for MOH.PubMedGoogle Scholar
  38. 38.
    •• De Felice M, Ossipov MH, Wang R, et al.: Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 2010, 133:2475–2488. These preclinical studies show potential clinical utility for nNOS inhibition in preventing or treating MOH.PubMedGoogle Scholar
  39. 39.
    Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28:183–187.PubMedCrossRefGoogle Scholar
  40. 40.
    Juhasz G, Zsombok T, Modos EA, et al.: NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003, 106:461–470.PubMedCrossRefGoogle Scholar
  41. 41.
    Sarchielli P, Alberti A, Codini M, et al.: Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000, 20:907–918.PubMedCrossRefGoogle Scholar
  42. 42.
    Friberg L, Olesen J, Olsen TS, et al.: Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia 1994, 14:47–54.PubMedCrossRefGoogle Scholar
  43. 43.
    •• Zhang X, Levy D, Noseda R, et al.: Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 2010, 30:8807–8814. (Published erratum appears in J Neurosci 2010, 30:10259.) This article includes preclinical evidence that induction of CSD leads to long-lasting activation of the nociceptors that innervate the meninges, suggesting that migraine with aura is initiated by waves of CSD that lead to activation of the trigeminovascular pathway.PubMedCrossRefGoogle Scholar
  44. 44.
    •• Supornsilpchai W, le Grand SM, Srikiatkhachorn A: Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia 2010, 30:1101–1109. This article includes observations that MOH might be due to alteration of cortical excitability, which leads to an increased susceptibility of CSD development.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Milena De Felice
    • 1
  • Michael H. Ossipov
    • 1
  • Frank Porreca
    • 1
  1. 1.Department of Pharmacology, College of MedicineUniversity of ArizonaTucsonUSA

Personalised recommendations